Amryt Pharma to Sell to Chiesi Farmaceutici in $1.48 Billion Cross-Border Transaction
January 9, 2023
Cooley advised Amryt Pharma, a Dublin, Ireland-based commercial-stage biopharmaceutical company, on its definitive agreement to be acquired by Chiesi Farmaceutici, a Parma, Italy-based research-focused biopharmaceuticals and healthcare group, in a $1.48 billion cash and contingent value right (CVR) transaction. Partners Bill Sorabella, Claire Keast-Butler and Bill Roegge led the joint US and UK Cooley team advising Amryt.
2C2P and Ant Group Partner to Accelerate Digital Payment Adoption
April 21, 2022
Cooley advised 2C2P, a global payments platform, on its strategic partnership with Ant Group, an innovative technology provider that strives to bring the world inclusive, green and sustainable services. Lawyers Matthew Bartus and Gwenlynne Lee led the Cooley team advising 2C2P.
Cooley advised the shareholders of ICS Learn, an online professional education platform owned by private equity firm Primary Capital Partners, on the platform’s sale to vocational e-learning provider Skill & You, a portfolio company of private equity firm IK Partners. Private equity partner Stephen Rosen led the Cooley team advising the shareholders of ICS Learn.
Chegg Agrees to Acquire Language Learning Platform Busuu
December 2, 2021
Cooley advised Chegg, a student-first connected learning platform, on its definitive agreement to acquire language learning platform Busuu for 385 million euros ($436 million). Partner Ben Shribman led the Cooley team advising Chegg.
Cooley advised Exscientia, an AI-driven pharmatech company based in Oxford, United Kingdom, on its $510.4 million initial public offering, including concurrent private placements to SoftBank and the Bill & Melinda Gates Foundation. Partners David Boles, Claire Keast-Butler, Div Gupta and Marc Recht led the Cooley team advising Exscientia.